Skip to content
Back to browse
SKIN Publication-derived

Skin Organoids at Air-Liquid Interface

Full SOP with Academic or a plan

Source Neal et al. · Stanford University, Stanford, USA · 10.1016/j.cell.2018.11.021

Authors: Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, Liu IH, Chiou SH, Salahudeen AA, Smith AR, Deutsch BC, Liao L, Zember AJ, Zhao F, Karlsson K, Schultz LM, Mber TJ, Grandber CC, Kuo CJ Duration: 30 days 9 phases Cell source: Patient-Derived (Multiple Cancer Types Including Melanoma)

Abstract

Landmark ALI organoid culture method preserving native tumor-infiltrating lymphocytes and stromal cells for up to 30 days. Enables checkpoint blockade testing recapitulating clinical responses across multiple cancer types including melanoma.

Cell source
Patient-Derived (Multiple Cancer Types Including Melanoma)
Application
Immunotherapy Testing with Native TME

Protocol overview

40 steps across 9 phases

Phase 1 · ALI Plate Preparation Day -1 to 0
  1. a Prepare reconstituted collagen matrix
  2. b Prepare ALI insert plates with bottom collagen layer
  3. c Solidify bottom collagen layer
Phase 2 · Human PDO Tissue Preparation and Primary Plating Day 0
  1. a Prepare tumor tissue
  2. b Resuspend tissue in collagen
  3. c Layer tissue-collagen mixture on top of pre-solidified collagen
  4. d Prepare organoid culture medium
  5. e Add medium to outer dish and initiate ALI culture
Phase 3 · PDO Culture Maintenance (Days 1-30) Days 1-30
  1. a Culture organoids at standard conditions
  2. b Replace medium every 3-4 days
  3. c Optional: Supplement with IL-2 to preserve immune cells
  4. d Monitor for necrotic tissue and assess viability
Phase 4 · PDO Passage and Serial Propagation Days 14-30 and beyond
  1. a Dissociate organoids using collagenase IV
  2. b Wash dissociated cells in fetal bovine serum
  3. c Replate dissociated tissue into new ALI collagen gels
  4. d Confirm viability with serial passage (P1)
  5. e Manage fibroblast overgrowth (if applicable)
Phase 5 · Cryopreservation and Recovery Variable (after P0 or P1)
  1. a Assess organoid suitability for cryopreservation
  2. b Dissociate and prepare organoid suspension
  3. c Freeze organoids slowly to –80°C, then transfer to liquid nitrogen
  4. d Thaw and recover organoids
Phase 6 · Anti-PD-1/PD-L1 Immune Checkpoint Blockade Treatment (Human PDOs) Days 0-7 (treatment window)
  1. a Establish PDOs and prepare for treatment
  2. b Prepare anti-PD-1 antibody (nivolumab) solution
  3. c Replace organoid culture medium with antibody-containing medium
  4. d Incubate organoids with antibody for 7 days
  5. e Harvest organoids for analysis (see Phases 7-9 for downstream assays)
Phase 7 · FACS Analysis of Immune Cells Day 7 (post-treatment)
  1. a Dissociate organoids to single cells
  2. b Prepare single-cell suspension for FACS
  3. c Stain cells with antibody cocktail for human PDO TILs
  4. d Wash and acquire cells by FACS
  5. e Quantify immune cell expansion and activation markers
Phase 8 · qRT-PCR Analysis of TIL Activation Markers Day 7 (post-treatment)
  1. a Sort TILs by FACS and extract RNA
  2. b Perform reverse transcription
  3. c Perform quantitative real-time PCR (qRT-PCR) for activation markers
  4. d Analyze and report qRT-PCR results
Phase 9 · Annexin V Apoptosis Assay for Tumor Cytotoxicity Day 7 (post-treatment)
  1. a Dissociate organoids to single cells
  2. b Pre-gate on tumor epithelial cells
  3. c Stain with Annexin V and 7-AAD
  4. d Acquire cells and identify apoptotic populations
  5. e Interpret results and report tumor cytotoxicity

Full SOP

Full SOPs need an account and a plan

Create an account, then get free Academic access (for verified academics) or choose a plan. Plans include step-by-step procedures, reagent concentrations, QC checklists and batch record templates.

Create an account

Already registered? Log in

Attribution

This SOP was written by Organthis based on the published method in Neal et al.. Once the originating laboratory has confirmed it, the SOP is marked Verified.

Something wrong with this entry? Report an issue with this protocol

Need a commercial licence?
Use this protocol in your therapeutic or diagnostic pipeline.
Request Commercial Licence